MarketCapExport financials
Altimmune (ALT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Altimmune Balance Sheet 2025-2009 | ALT
Brief overview of Altimmune's financial position
The review uses the five latest available annual reports between 2021 and 2025.
Assets increased from $218.9 million to $279.9 million, or +27.9%; CAGR of about 6.3% indicates steady balance sheet expansion.
Liabilities expanded faster than the asset base, +179% versus +27.9%. Debt-service capacity deserves attention.
The equity-to-assets ratio is 80.3%, compared with 91% five periods ago. The balance sheet has a substantial internal cushion.
The period ended with net cash: net debt stood at -$9.2 million. This supports financial flexibility.
Cash represents 15.6% of assets versus 86.9% initially, showing how the immediate liquidity reserve changed.
The balance sheet includes a negative accumulated result of -$649.5 million. It should be assessed alongside historical profits and capital distributions.
Conclusion
Altimmune's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.
Annual Balance Sheet Altimmune
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-9.22 M | -35.2 M | -134 M | -106 M | -188 M | -114 M | -7.22 M | -33.1 M | -8.12 M | -153 M | -15.6 M | -17.9 M | -7.66 M | -8.92 M | -11.2 M | - | - |
Long Term Debt |
34.3 M | 1.4 M | 175 K | 4.58 M | 1.45 M | - | - | 501 K | 600 K | - | - | - | 730 K | 1.7 M | - | - | - |
Long Term Debt Current |
256 K | 279 K | 496 K | 452 K | 411 K | 357 K | 259 K | - | - | - | - | 746 K | 1 M | 750 K | - | - | - |
Total Non Current Liabilities |
- | 5.33 M | 4.4 M | 4.58 M | - | 7.22 M | 4.61 M | 1.91 M | 10.5 M | 443 K | 1.03 M | 1.12 M | 3.01 M | 3.58 M | 2.34 M | - | - |
Total Current Liabilities |
15 M | 10.5 M | 12.1 M | 17.1 M | 18.3 M | 12 M | 3.92 M | 4.53 M | 3.84 M | 205 M | 2.18 M | 2.58 M | 6.8 M | 7.49 M | 4.62 M | 6.16 M | - |
Total Liabilities |
55 M | 15.8 M | 16.5 M | 21.6 M | 19.7 M | 19.2 M | 8.54 M | 6.44 M | 14.4 M | 205 M | 3.21 M | 3.7 M | 9.8 M | 11.1 M | 6.95 M | 15 M | - |
Deferred Revenue |
- | - | - | - | - | 19.8 K | 61.6 K | 19.8 K | 19.8 K | - | - | - | 342 K | 1.38 M | - | - | - |
Retained Earnings |
-649 M | -561 M | -466 M | -378 M | -293 M | -186 M | -137 M | -117 M | -77.7 M | -29.9 M | -224 M | -220 M | -210 M | -199 M | -194 M | -190 M | - |
Total Assets |
280 M | 139 M | 211 M | 207 M | 219 M | 245 M | 54.1 M | 54.8 M | 63 M | 225 M | 19.9 M | 22 M | 17.1 M | 22.7 M | 22.8 M | 27.2 M | - |
Cash and Cash Equivalents |
43.8 M | 36.9 M | 135 M | 111 M | 190 M | 116 M | 8.96 M | 33.7 M | 8.77 M | 154 M | 15.6 M | 18.6 M | 10.5 M | 12.7 M | 11.2 M | 11.8 M | 2.67 M |
Book Value |
225 M | 124 M | 194 M | 185 M | 199 M | 226 M | 45.5 M | 48.3 M | 48.7 M | 19.5 M | 16.6 M | 18.3 M | 7.34 M | 11.7 M | 15.9 M | 12.2 M | - |
Total Shareholders Equity |
225 M | 124 M | 194 M | 185 M | 199 M | 226 M | 45.5 M | 48.3 M | 39.4 M | 32.2 M | 16.6 M | 18.3 M | 7.34 M | 11.7 M | 15.9 M | 12.2 M | 3.15 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Altimmune
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
1.14 M | 34.5 M | 1.4 M | 14.4 M | 14.3 M | 1.34 M | 1.4 M | 1.46 M | 1.52 M | - | 175 K | 4.3 M | 4.16 M | 4.4 M | 4.58 M | 4.51 M | 1.53 M | 1.67 M | 1.45 M | 1.57 M | 1.62 M | 1.72 M | 1.83 M | 1.83 M | 1.83 M | 1.83 M | 1.86 M | 1.86 M | 1.86 M | 1.86 M | 1.85 M | 1.85 M | 1.85 M | 1.85 M | 600 K | 590 K | 571 K | - | 526 K | - | 526 K | - | - | - | - | - | - | 993 K | 240 K | 485 K | 730 K | 730 K | 730 K | 730 K | 1.7 M | 1.7 M | 1.7 M | 1.7 M | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 5.3 M | 5.33 M | 5.85 M | 5.66 M | - | 4.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
55 M | 51.6 M | 15.8 M | 32.8 M | 29 M | 15.1 M | 15.8 M | 14.5 M | 20.8 M | - | 16.5 M | 16.2 M | 15.6 M | 19.4 M | 21.6 M | 20.2 M | 15.4 M | 20.8 M | 19.7 M | 27.6 M | 16 M | 17.8 M | 19.2 M | 19.2 M | 19.2 M | 19.2 M | 8.54 M | 8.54 M | 8.54 M | 8.54 M | 6.44 M | 6.44 M | 6.44 M | 6.44 M | 14.4 M | 14.4 M | 14.4 M | 14.4 M | 6.19 M | 6.19 M | 6.19 M | 205 M | 3.21 M | 3.21 M | 3.21 M | 3.21 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 9.8 M | 9.8 M | 9.8 M | 9.8 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 6.95 M | 6.95 M | 6.95 M | 6.95 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.8 K | 58 K | 19.8 K | 19.8 K | 19.8 K | 19.8 K | 19.8 K | 61.6 K | 61.6 K | 61.6 K | 61.6 K | 19.8 K | 19.8 K | 19.8 K | 19.8 K | 19.8 K | 19.8 K | 19.8 K | 19.8 K | 19.8 K | 19.8 K | 19.8 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-649 M | -672 M | -561 M | -622 M | -603 M | -581 M | -561 M | -538 M | -515 M | - | -466 M | -435 M | -414 M | -398 M | -378 M | -356 M | -333 M | -313 M | -293 M | -269 M | -236 M | -211 M | -186 M | -186 M | -186 M | -186 M | -137 M | -137 M | -137 M | -137 M | -117 M | -117 M | -117 M | -117 M | -77.7 M | -77.7 M | -77.7 M | -77.7 M | -31.3 M | -31.3 M | -31.3 M | -29.9 M | -224 M | -224 M | -224 M | -224 M | -220 M | -220 M | -220 M | -220 M | -210 M | -210 M | -210 M | -210 M | -199 M | -199 M | -199 M | -199 M | -194 M | -194 M | -194 M | -194 M |
Total Assets |
280 M | 336 M | 139 M | 218 M | 190 M | 157 M | 139 M | 148 M | 173 M | - | 211 M | 167 M | 183 M | 187 M | 207 M | 225 M | 210 M | 206 M | 219 M | 237 M | 257 M | 264 M | 245 M | 245 M | 245 M | 245 M | 54.1 M | 54.1 M | 54.1 M | 54.1 M | 54.8 M | 54.8 M | 54.8 M | 54.8 M | 63 M | 63 M | 63 M | 63 M | 38.4 M | 38.4 M | 38.4 M | 225 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 22 M | 22 M | 22 M | 22 M | 17.1 M | 17.1 M | 17.1 M | 17.1 M | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 22.8 M | 22.8 M | 22.8 M | 22.8 M |
Cash and Cash Equivalents |
37 M | 97.6 M | 135 M | 61.2 M | 183 M | 49.1 M | 36.9 M | 31.5 M | 57.2 M | 79 M | 135 M | 86.9 M | 102 M | 105 M | 111 M | 127 M | 136 M | 180 M | 190 M | 175 M | 174 M | 150 M | 116 M | 116 M | 116 M | 116 M | 8.96 M | 8.96 M | 8.96 M | 8.96 M | 33.7 M | 33.7 M | 33.7 M | 33.7 M | 8.77 M | 8.77 M | 8.77 M | 8.77 M | 2.88 M | 2.88 M | 2.88 M | 154 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 18.6 M | 18.6 M | 18.6 M | 18.6 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M |
Book Value |
225 M | 284 M | 124 M | 186 M | 161 M | 142 M | 124 M | 133 M | 153 M | - | 194 M | 150 M | 168 M | 168 M | 185 M | 205 M | 195 M | 185 M | 199 M | 209 M | 241 M | 246 M | 226 M | 226 M | 226 M | 226 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 48.3 M | 48.3 M | 48.3 M | 48.3 M | 48.7 M | 48.7 M | 48.7 M | 48.7 M | 32.2 M | 32.2 M | 32.2 M | 19.5 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 18.3 M | 18.3 M | 18.3 M | 18.3 M | 7.34 M | 7.34 M | 7.34 M | 7.34 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 15.9 M | 15.9 M | 15.9 M | 15.9 M |
Total Shareholders Equity |
124 M | 284 M | 194 M | 186 M | 161 M | 142 M | 124 M | 133 M | 153 M | 173 M | 194 M | 150 M | 168 M | 168 M | 185 M | 205 M | 195 M | 185 M | 199 M | 209 M | 241 M | 246 M | 226 M | 226 M | 226 M | 226 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 48.3 M | 48.3 M | 48.3 M | 48.3 M | 39.4 M | 39.4 M | 39.4 M | 39.4 M | 32.2 M | 32.2 M | 32.2 M | 19.5 M | 43.1 M | 16.6 M | 16.6 M | 16.6 M | 18.3 M | 18.3 M | 18.3 M | 18.3 M | 7.34 M | 7.34 M | 7.34 M | 7.34 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 15.9 M | 15.9 M | 15.9 M | 15.9 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Altimmune, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Exelixis
EXEL
|
$ 69.55 | 1.22 % | $ 18.9 B |  USA |
 |
Geron Corporation
GERN
|
$ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
$ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
$ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
$ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
$ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
$ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
$ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
- | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
$ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
$ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
$ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
- | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
$ 0.39 | 0.15 % | $ 1.91 M | USA |
 |
TFF Pharmaceuticals
TFFP
|
- | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 1.63 | 1.87 % | $ 2.68 M |  Israel |
 |
Mesoblast Limited
MESO
|
$ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
$ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
- | - | $ 521 M | USA |
 |
Codexis
CDXS
|
$ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
$ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
$ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Axcella Health
AXLA
|
- | -16.42 % | $ 249 M | USA |
 |
Merck & Co.
MRK
|
$ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
- | - | $ 2.02 B | USA |
 |
Tyme Technologies
TYME
|
- | 8.07 % | $ 54 M | USA |
 |
Curis
CRIS
|
$ 0.88 | 3.67 % | $ 11.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
$ 34.99 | 3.77 % | $ 147 M | USA |
 |
Завод ДИОД
DIOD
|
- | - | - |  Russia |
 |
CorMedix
CRMD
|
$ 5.31 | 1.43 % | $ 383 K | USA |
 |
Novartis AG
NVS
|
$ 162.64 | 0.44 % | $ 315 B |  Schweiz |
 |
CRISPR Therapeutics AG
CRSP
|
$ 50.09 | 3.15 % | $ 4.5 B | Schweiz |
 |
PDS Biotechnology Corporation
PDSB
|
$ 1.22 | 4.27 % | $ 56.6 M | USA |
 |
Pfizer
PFE
|
$ 29.39 | -0.22 % | $ 167 B | USA |
 |
Pharming Group N.V.
PHAR
|
$ 12.32 | 0.16 % | $ 8.49 B |  Niderland |
 |
Orgenesis
ORGS
|
- | -33.86 % | $ 61.2 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
$ 53.74 | -3.26 % | $ 6.45 M | USA |
 |
Фармсинтез
LIFE
|
- | - | - | Russia |
 |
Prothena Corporation plc
PRTA
|
$ 7.93 | 0.51 % | $ 427 M | USA |
 |
Codiak BioSciences
CDAK
|
- | -55.98 % | $ 2.15 M | USA |
 |
DBV Technologies S.A.
DBVT
|
$ 10.54 | 7.55 % | $ 1.47 B |  France |
 |
Rocket Pharmaceuticals
RCKT
|
$ 2.38 | -2.05 % | $ 264 M | USA |
 |
Regeneron Pharmaceuticals
REGN
|
$ 904.69 | 0.2 % | $ 94.6 B | USA |
 |
Replimune Group
REPL
|
$ 21.67 | 8.24 % | $ 2.01 B | USA |
 |
DiaMedica Therapeutics
DMAC
|
$ 9.47 | 4.76 % | $ 445 M | USA |
 |
Royalty Pharma plc
RPRX
|
$ 67.31 | -0.39 % | $ 28.9 B | USA |